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ABSTRACT
Introduction: Psychological distress is common in
end-stage kidney disease (ESKD) and is associated
with poorer health outcomes. Cognitive behavioural
therapy (CBT) is recommended in UK clinical
guidelines for the management of depression in people
with long-term conditions. Access to skilled therapists
competent in managing the competing mental and
physical health demands of ESKD is limited. Online
CBT treatments tailored to the needs of the ESKD
population offers a pragmatic solution for under-
resourced services. This study examines the feasibility
and acceptability of implementing a two-arm parallel
randomised controlled trial of online CBT with
(intervention arm) and without (control arm) therapist
support to improve psychological distress in patients
undergoing haemodialysis.
Methods: Patients will be screened for depression
and anxiety while attending for their haemodialysis
treatments. We aim to recruit 60 adult patients
undergoing haemodialysis who meet criteria for mild
to moderately severe symptoms of depression and/or
anxiety. Patients will be randomised individually (using
a 1:1 computerised sequence ratio) to either online
CBT with therapist telephone support (intervention
arm), or online CBT with no therapist (control arm).
Outcomes include feasibility and acceptability
descriptive data on rates of recruitment, randomisation,
retention and treatment adherence. Self-report
outcomes include measures of depression (Patient
Health Questionnaire-9), anxiety (Generalised Anxiety
Disorder-7), quality of life (Euro-QoL), service use
(client service receipt inventory) and illness cognitions
(brief illness perception questionnaire). A qualitative
process evaluation will also be conducted. The
statistician will be blinded to treatment allocation.
Ethics and dissemination: A National Health
Service (NHS) research ethics committee approved the
study. Data from this study will provide essential
information for the design and testing of further
interventions to ameliorate distress in patients
undergoing dialysis. Any amendments to the protocol
will be submitted to the NHS committee and study
sponsor.
Trial registration number: NCT023528702;
Pre-results.
INTRODUCTION
End-stage kidney disease (ESKD) is a chronic
condition that permanently affects kidney
Strengths and limitations of this study
▪ This protocol provides a framework for the
design and evaluation of an online cognitive
behavioural therapy treatment for the manage-
ment of comorbid distress and end-stage renal
disease.
▪ First feasibility study to evaluate cognitive behav-
ioural therapy using online pragmatic delivery
methods in a UK National Health Service (NHS)
haemodialysis setting.
▪ Recruitment from a single UK NHS site may
hinder generalisabilty of feasibility outcomes.
▪ Patient treatment preferences are not accounted
for. However, such designs would be associated
with increased costs, a prohibitive factor in the
current study, and increase the potential for con-
founding factors.
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function.1 Without renal replacement therapy (eg, dialy-
sis or transplantation) a person’s physical health would
rapidly deteriorate because of the build-up of toxins and
waste products in the body.2 In addition to renal replace-
ment therapy, patients are required to attend regular
clinical appointments, take multiple medications, and
adhere to rigid dietary and ﬂuid restrictions.3
Psychological distress is common in ESKD with an esti-
mated prevalence of 39% among people in receipt of
dialysis compared with a prevalence of 27% in patients
with chronic kidney disease (stages 1–5).4 Comorbid psy-
chological distress and ESKD are associated with higher
rates of mortality5 and healthcare usage.6 The safety and
efﬁcacy of pharmacotherapy in managing psychological
distress among people with ESKD remains unclear
because of a lack of robust randomised controlled trials
(RCTS).7 Although talking therapies likely offer a safer
alternative to pharmacotherapy, their efﬁcacy in the
ESKD population is largely unknown. Only two
small-scale, non-UK based, RCTs have examined the efﬁ-
cacy of cognitive behavioural therapy (CBT) relative to
usual care among patients undergoing haemodialysis.8 9
Both trials found CBT was effective in reducing psycho-
logical distress. These ﬁndings are consistent with larger
scale RCTs of CBT treatments for depression in people
with coronary heart disease.10
The NHS has limited resources to allow the demand
for CBT therapist time to be met adequately. A practical
approach to address this problem is to implement a
stepped-care health service delivery model.11 Within this
model, individuals begin with low-intensity interventions
unless their distress is deemed too severe to beneﬁt
from the type of minimal intervention offered.
Providing low-intensity treatments means that there is
decreased treatment burden for patients, but equally,
health services can treat a larger volume of patients. If
necessary, a patient is ‘stepped up’ to receive more
intensive intervention if the initial low-intensity treat-
ment did not improve outcomes.
Guided self-help CBT treatments are considered low-
intensity interventions12 and are effective in the manage-
ment of psychological distress in people with13 and
without comorbid physical health conditions.14 Online/
computerised self-help resources allow better manage-
ment of the informational needs of patients, and
encourage active engagement with treatment by interact-
ing with the online interface.15 Indeed, in people
without physical health conditions, online/computerised
guided self-help treatments have largely demonstrated
equivalence with face-to-face psychological interventions
in terms of their clinical effectiveness (depression and
anxiety)16 and degree of adherence to treatment
sessions.17
However, there are a number of factors that determine
the efﬁcacy of online and computerised self-help treat-
ments. One moderating factor is whether support is pro-
vided by a healthcare professional. Online/computerised
self-help treatments with support from healthcare
professionals improves outcomes and prevents treatment
dropout.18 19 The type of support provided is also import-
ant. A recent RCT explored the efﬁcacy of online CBT
with weekly technical/motivational support calls from a
non-clinician for the management of depression, and
compared it with usual general practitioner (GP) care.20
Its ﬁndings conﬁrmed that providing patients with access
to online CBT with only technical support had no added
beneﬁt on depression outcomes compared with GP usual
care. Access to a skilled therapist is especially important
in the context of comorbid mental and physical health
conditions because of the potential for treatment antag-
onisms, whereby the effective management of a person’s
mental health has the potential to dysregulate the man-
agement of physical health or vice versa.21
Given that the evidence points to the efﬁcacy of
online/computerised treatments with therapeutic
support for the management of psychological distress in
people with and without physical long-term condition
(LTCs), it remains uncertain whether these ﬁndings
apply to the management of psychological distress in UK
NHS haemodialysis treatment settings. This study seeks
to explore the feasibility and acceptability of implement-
ing a two-arm parallel RCT of online CBT with (interven-
tion arm) and without (control arm) therapist support
to improve psychological distress in people receiving
haemodialysis treatments within a stepped-care health
service delivery framework.
Background to the study
The development of the improving distress in dialysis
(iDiD) online CBT treatment involved a multidisciplin-
ary team of health psychologists, clinical psychologists,
psychiatrists, nephrologists and six patient and public
involvement representatives. The preliminary content of
the website was initially determined by self-help
resources used to manage adjustment outcomes in LTCs
implemented in previous trials by one of our authors
(RMM).22–24 In addition, a literature review of the corre-
lates of distress in dialysis was used to develop an
ESKD-speciﬁc CBT treatment formulation and seven-
session protocol ( JL Hudson, R Moss-Morris, D Game,
et al. Improving distress in dialysis (iDiD): a tailored
CBT treatment for dialysis patients. Under review. 2016).
In brief, our CBT formulation recognises the unique
acute and chronic stressors that occur in the dialysis
population including: ESKD diagnosis, surgical proce-
dures needed for vascular access site generation, loss of
independence, changes in body and self-image, uncer-
tainty about health and future, the unseen burden of
kidney disease, and chronic illness self-management
challenges, speciﬁcally managing thirst and food crav-
ings, and dealing with health professionals. CBT inter-
vention techniques for managing these illness-speciﬁc
stressors are then introduced in subsequent online treat-
ment sessions. The content of each treatment session
was ﬁrst drafted on paper and reviewed by the research
team. Patient representatives then provided feedback on
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the relevance and ease of understanding of the informa-
tion and CBT intervention techniques described. Next,
the intervention content was uploaded onto an online
platform using LifeGuide software.25 The presentation
and navigation through the website was tested using
patient representatives and ‘think-aloud’ techniques.
This process occurred iteratively so that comments on
early sessions could be incorporated into the design of
subsequent sessions.
The intervention includes a total of seven sessions.
The content of each session is summarised in online
supplementary table S1. For more detailed information,
see our distress in dialysis CBT treatment formulation
model ( JL Hudson, et al. Improving distress in dialysis
(iDiD): a tailored CBT treatment for dialysis patients.
Under review. 2016). Patients are encouraged to com-
plete one session per week, and each session was
designed to last approximately 1 hour in duration.
OBJECTIVES
The following aims will be addressed as part of a feasibil-
ity and acceptability parallel RCT of online CBT with
and without therapist support, delivered within a
stepped-care framework among outpatient patients
undergoing haemodialysis, with comorbid psychological
distress:
▸ To assess the feasibility and acceptability of screening
all patients who attend for haemodialysis. Patients will
be screened for depression and anxiety using standar-
dised measures presented on iPADs. The presence of
psychological distress is often not identiﬁed by non-
mental health-trained clinicians.26 Implementing
screening questionnaires for psychological distress in
medical settings can promote its detection27 and,
ultimately, the provision of mental healthcare. We will
quantify the number of people who agree to be
screened.
▸ To explore rates of recruitment and retention into
the trial.
▸ To examine willingness to be randomised to either
the intervention arm (with telephone support) or
control arm (no telephone support) by recording
participant reasons for non-consent into the study (if
disclosed).
▸ To explore the level of adherence to online treatment
sessions and telephone support calls (intervention
arm only).
▸ To explore the potential efﬁcacy of an online inter-
vention with therapist-led telephone support in redu-
cing psychological distress when compared with
website alone. This will inform the planning of a
future full-scale trial to detect clinically meaningful
change in outcomes of psychological distress.
▸ To examine if change in quality of life differs
between the intervention arm and control arm.
▸ To provide a preliminary assessment of the cost-
effectiveness of the intervention.
▸ To examine change in ESKD illness cognitions, and
whether their effect differs between the intervention
and control arm.
▸ To qualitatively explore patient perceptions of the
acceptability and usability of the website and tele-
phone support calls, and identify areas of improve-
ment for future interventions.
METHODS
Design
A two-arm parallel randomised controlled feasibility trial
(RCT). Participants will be randomised, individually,
using a 1:1 ratio computerised algorithm. A nested quali-
tative study will evaluate patient experience.
Setting and participants
Participants will be recruited from haemodialysis units at
Guy’s and St Thomas’ hospital (London, UK).
Participants will be eligible for inclusion if:
▸ aged 18 years or over, and receive hospital haemodi-
alysis three times weekly;
▸ they have mild to moderately severe depressive symp-
toms (based on PHQ-928 scores of 5–19; a self-report
measure of depression) and/or presence of mild to
moderately severe anxiety symptoms (based on self-
report GAD-729 scores of 5–14);
▸ they speak English sufﬁciently well to engage with
screening tools;
▸ they have a basic understanding of how to use the
internet and an email address.
Participants will be ineligible if
▸ currently receiving active treatment for depression
and/or anxiety. Active treatment is deﬁned as any
current psychological treatment (talking therapies)
or receipt of a new antidepressant and/or antianxiety
medication. A medication is considered new if started
3 months prior to the completion of the depression
and anxiety screening questionnaire;
▸ they have a severe mental health disorder, for
example, psychosis, bipolar disorder;
▸ they have active suicidal thoughts, as indicated by a
score of >1 on the depression PHQ-9 item ‘Thoughts
that you would be better off dead, or of hurting
yourself’;
▸ they have evidence of addiction to alcohol or drugs.
A participant will be withdrawn from the study if
there are safety concerns in relation to their physical
or mental health
▸ the participant chooses to withdraw from the study
▸ a patient’s level of psychological distress deteriorates.
Flow of recruitment and participant timeline
Participants will be identiﬁed for inclusion using web-
based screening questionnaires routinely used as part
of the Integrating Mental and Physical healthcare:
research, training and services (IMPARTS) initiative at
Guy’s and St Thomas’ hospital.30 Participants consenting
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to the screen will be assessed for depression and anxiety
using the PHQ-931 and GAD-7,29 respectively. The
PHQ-9 is a nine-item self-report questionnaire deemed
acceptable for the identiﬁcation of depression in
medical care settings, including specialist settings.27
Likewise, the GAD-7, is a self-report seven-item question-
naire with evidenced criterion validity for the detection
of generalised anxiety disorder.29 The PHQ-9 and
GAD-7 are routinely used in UK primary care Improving
Access to Psychological Therapy (IAPT) sites32 to
monitor patient outcomes. The patient will complete
the web-based questionnaires either alone or with the
assistance of a renal nurse/researcher. While completing
the screening questionnaire, patients will be asked to
give their permission (yes/no) for a member of the
research team to contact them about the present study.
Results from the screening questionnaires are
uploaded onto the patient’s electronic medical record.
Results will be checked by the nursing team/researcher
for immediate risk. Risk is deﬁned as a score of >1 on
the depression PHQ-9 item ‘Thoughts that you would be
better off dead, or of hurting yourself’. If suicidal idea-
tion is detected, then a risk assessment will be per-
formed to determine the immediacy of referral to either
liaison psychiatry or renal clinical psychology. Level of
risk will be assessed in line with the IMPARTS risk assess-
ment protocol. This includes enquiring about degree of
suicidal ideation and level of hopelessness, whether
active plans are present, enquiring about the patient’s
history of suicide attempts, recent life stressors, protect-
ive factors and degree of social support. The outcome of
the risk assessment will be immediately discussed with
either the renal clinical psychologist or liaison psych-
iatrist, and a management plan will be put into place.
Anonymised screening results will be securely emailed
from the IMPARTS database to the iDiD research team
on a weekly basis. A stratiﬁed stepped-care model,
according to the criteria outlined in ﬁgure 1 will be
applied to the anonymised data to identify potentially
eligible participants for the study. The stratiﬁed stepped-
care approach assigns individuals to treatments of
varying intensity based on the severity of their symp-
toms.33 PHQ-9 scores within the range of 5–19, are con-
sidered indicative of mild to moderately severe
symptoms of depression.31 Likewise, GAD-7 scores within
the range of 5–14 indicate the presence of mild to mod-
erately severe anxiety.29 Individuals with mild to moder-
ately severe symptoms of depression and/or anxiety will
be considered appropriate for treatment with the iDiD
online CBT programme, and for inclusion in this study.
Individuals with severe depression (PHQ-9 score≥20)
and/or anxiety (GAD7 score ≥15), or individuals with
evidence of current suicidal ideation are considered
inappropriate for iDiD online CBT. These patients will
be referred and managed by either the renal clinical
psychology team or liaison psychiatry (when detected at
the point of screen).
Individuals who meet the criteria for mild to moder-
ately severe symptoms of depression and/or anxiety will
have their data de-anonymised providing they give us
consent to contact them about the study. These poten-
tial participants will be screened against the remaining
inclusion/exclusion criteria during weekly referral meet-
ings with the research and clinical team. If they remain
eligible a researcher will approach the participant while
they attend dialysis, to explain the study with the partici-
pant information sheet. Participants will be given a
minimum of 24 h to establish if they would like to take
part.
All patients with mild to moderately severe symptoms
of depression and/or anxiety who either: (1) do not
meet our remaining study inclusion criteria, (2) choose
not to consent into the study, or (3) do not provide
consent for us to approach them about the study, will be
provided with the option of receiving usual care
follow-up from the renal clinical psychology team. Usual
Figure 1 Stratified stepped-care referral pathway for managing psychological distress among individuals attending for
haemodialysis.
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care includes a face-to-face clinical assessment followed
by a tailored psychological treatment intervention or
referral to an IAPT service.
As discussed above, patients who screen positive for
severe symptoms of depression and/or anxiety (PHQ-9
score ≥20 and/or GAD7 score ≥15) will receive an auto-
matic referral to the renal clinical psychology team. If
on clinical assessment by the renal clinical psychologist a
severely depressed and/or anxious patient is deemed
appropriate for the iDiD self-help study, then they will
be ‘stepped down’ for approach by the iDiD research
team. Likewise, the research team will be informed by
the renal clinical psychology team of any patients who
meet the iDiD study inclusion criteria, and declare an
interest in the study despite initially stating during
screening that they did not want to be contacted by the
study team.
Participants who consent to take part in the study will
be issued with an iDiD study identiﬁcation number. A
researcher will attend the dialysis unit and help the
patient to sign-up to the iDiD online CBT treatment
using an iPAD. At sign-up, participants will be asked to
enter their personal email address and select a password
for use each time they logon. At the point of sign-up
participants will also be asked to enter their NHS
number (supplied to them by the researcher) to ensure
that multiple iDiD accounts are not registered by the
same participant. Participants will then receive a con-
ﬁrmatory email with a link to the iDiD website. After
signing up, participants will complete the baseline ques-
tionnaires online. If baseline questionnaires are not
completed, then participants will receive two reminder
emails and an assistance-based telephone call/visit at the
dialysis unit. Participants will be informed of the
outcome of their randomisation process immediately
after completing the online baseline questionnaire.
Participants will also receive an email conﬁrming their
treatment allocation. We anticipate the participant’s
journey through the study will last approximately
6 months, as summarised in ﬁgure 2. We expect a
period of 1 month to elapse from the point of screening
to randomisation. Once participants are randomised,
both groups will be able to access the iDiD website for a
period of 12 weeks before being prompted to complete
the follow-up questionnaires via email. The email will
also advise participants that their access to the iDiD
website is ending within a few weeks, and to print out
any information they have found helpful from the ‘My
tasks’ tab of the website. Two reminder emails and an
assistance-based telephone call/visit will occur over a
period of 3 weeks if the follow-up questionnaires remain
incomplete. After 20 weeks, participants will receive an
email thanking them for their participation in iDiD
study. Access to the iDiD website will no longer be avail-
able after this time. On completion of the 3-month
follow-up questionnaires, a subsample of participants
will be asked to complete a qualitative interview. We will
follow-up participants for a period of approximately
6 months post their randomisation date, to complete the
interview.
Randomisation, allocation concealment and blinding
Participants will be randomised to iDiD online CBT plus
therapist-led telephone support, or iDiD online
CBT-only condition using Lifeguide software (a compu-
terised random number generator with a 1:1 ratio).
Because the randomisation sequence is automated by
Lifeguide in real time, the allocation sequence is con-
cealed from researchers. All baseline questionnaires will
be completed online prior to randomisation.
Participants will be randomised at the individual level.
The trial coordinator will also receive an automated
email informing them of the outcome of the randomisa-
tion procedure to identify participants who require tele-
phone support calls during the trial. The researcher
conducting the qualitative interviews will also be
unblinded at follow-up to ensure that appropriate ques-
tions are asked in relation to telephone support calls.
Owing to the nature of the intervention, patients will
not be blind to their treatment allocation. Follow-up out-
comes will be completed independently by participants
Figure 2 Flow of participants through the study.
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when prompted by email unless the participant requires
assistance. The statistician will remain blinded to treat-
ment allocation.
Trial intervention
All participants have access to the iDiD online CBT treat-
ment (summarised in online supplementary table S1
and described in detail in our ESKD CBT formulation
model) ( JL Hudson, et al. Improving Distress in Dialysis
(iDiD): A tailored CBT treatment for dialysis patients.
Under review. 2016). Participants will be advised in the
participant information sheet to logon to the website
once a week. Participants will also receive weekly
reminder emails to encourage engagement with the
website. iPADs will be available for participants to use
during their dialysis sessions.
iDiD online CBT website plus therapist-led telephone support
(intervention arm)
Participants in the intervention arm of the trial will
receive three 30 min telephone support calls at weeks 2,
4 and 6 from JLH who has a PhD in health psychology
and is a trained psychological well-being practitioner
(PWP). PWPs typically work in primary care mental
health teams as part of the UK Improving Access to
Psychological Therapies initiative.32 PWPs deliver low-
intensity CBT treatments including: cognitive restructur-
ing, behavioural activation, problem solving, medication
management, exposure therapy and sleep management.
The purpose of the telephone support calls are to
promote engagement with the website and to support
the patient in collaboratively developing goals to work
on using the resources and information available to
them on the website. At the start of each telephone call,
the PWP will set an agenda with the participant. The
ﬁrst telephone support call is scheduled for when the
participant will have completed session two online.
During session two the participant will have completed a
self-assessment and developed their own personal model
of distress. Thus, during the ﬁrst call, the PWP will
develop a shared understanding of the participant’s
source of distress, provide empathy, reinforce with the
participant the relationships between thoughts, feelings
and behaviours, and inform participants of the content
the website which is likely most applicable to them as
they continue to move forward with the website. The
PWP and patient will develop a goal to work towards
prior to their next telephone call.
The second telephone support call will provide an
opportunity for the PWP to review with the participant
their progress on their self-generated goals, work
through a particular cognitive behavioural intervention
technique selected by the participant, and close the
session with a shared goal to work towards with the help
of the website in advance of the ﬁnal telephone support
call. The ﬁnal telephone support call will follow a
similar format except the telephone session will end
with a relapse prevention plan. The plan will be
generated collaboratively with the patient. All telephone
support calls will be audio-recorded to provide interven-
tion ﬁdelity checks, and for self-reﬂection during clinical
supervision.
Clinical supervision
JLH was trained to deliver the telephone support calls
using role-played sessions with feedback from
RM-M. Ongoing supervision will be provided by a renal
clinical psychologist (AC). Shared reﬂection on audio-
recorded sessions will be discussed in line with the core
competency framework for delivering psychological ther-
apies in long-term conditions.34 Shared goals will be
identiﬁed for the PWP to work towards over the course
of the study. Supervision will also be an opportunity for
case management. The PWP will discuss their proposed
treatment plan in response to the ﬁrst telephone
support call and degree of patient progress at each
supervision session. If a patient needs to be stepped-up
to receive more intensive psychological treatments then
this will be initiated by the research team and managed
by the renal clinical psychologist.
iDiD online CBT website with no telephone support
(control arm)
Participants allocated to the control arm of the study
will receive their usual renal care in addition to having
access to the website. Usual care for individuals with
ESKD managed with haemodialysis includes attending
for dialysis three times per week for up to 5 h at a time.
Participants can be referred or self-refer into the renal
clinical psychology service, or primary care mental
health service, if their symptoms of depression and/or
anxiety increase. We will ask participants in the 3-month
follow-up questionnaire whether they have started any
new treatments for mental health since starting the
study.
OUTCOMES
Data collection and feasibility outcomes
Since this is a feasibility study, our primary focus is to
collect data on the feasibility and acceptability of the
trial design and intervention by collecting descriptive
data on recruitment and retention rates and willingness
to be randomised according to CONSORT trial guide-
lines.35 We will also examine adherence to the online
intervention and telephone support calls (intervention
arm only). The degree of adherence to the online inter-
vention will be automatically recorded by the Lifeguide
software. We will calculate descriptive values for the
mean number of sessions completed, the number of par-
ticipants who complete all sessions, the number of parti-
cipants who complete 50% or more sessions and the
number of participants who complete each session.
Degree of adherence to the telephone call (intervention
arm only) will be recorded by the PWP. The following
values will be calculated: mean number of telephone
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calls completed, number of participants who complete
all telephone calls, number who complete one or more
telephone call, number of participants who complete
telephone sessions one, two and three, respectively and
mean duration of telephone calls across all three tele-
phone support calls. In addition to a qualitative inter-
view (described below) patients will be asked to
self-report their experience of using the iDiD website at
3 months follow-up. The open-ended questions will
enquire about: (1) how useful they found the iDiD
website and (2) whether they found the website easy to
use. Participants will also be given the option to add any
further comments.
Self-reported patient outcomes will also be collected
via the iDiD website at baseline and 3 months follow-up.
The assessment schedule completed by patients is sum-
marised in table 1 and described below:
▸ Continuous self-report measure of depression:
PHQ-931 (described in detail above, scale range from
0 to 27, high scores indicate greater depressive
symptoms).
▸ Continuous self-report measure of anxiety: (GAD-7)29
(described in detail above, scale range from 0 to 21,
high scores indicate greater anxiety symptoms).
▸ The ﬁve-item EuroQoL (EQ-5D)36 includes a
ﬁve-item measure of health status across the following
domains: mobility, ability to self-care, ability to con-
tinue with activities (ie, work, social life), pain and
anxiety and depression. In addition, it has a visual
analogue scale ranging from 0 to 100 where a person
is asked to rate their overall health. The EQ-5D is
recommended by NICE for use in cost-effectiveness
evaluations.37
▸ The Client Service Receipt Inventory (CSRI)38 col-
lects retrospective data on service use across the fol-
lowing ﬁve domains: (1) background and client
information (ie, hospital admissions and discharge,
frequency of GP visits, medications), (2) accommoda-
tion and living situation, (3) employment history,
earnings and other personal resources, (4) service
receipt (ie, hospital appointments, home help) and
(5) receipt of informal care from caregivers. The
CSRI was amended to make its content relevant to
the needs of the dialysis population in collaboration
with the trial health economist (PM) and renal con-
sultant (DG).
▸ The brief illness perception questionnaire (BIPQ)39
will assess participants self-reported beliefs about
their ESKD. The BIPQ was developed and validated
among patients with long-term conditions, including
renal disease. This information will be assessed at
baseline and follow-up. It will provide an indication
of whether participants’ beliefs about their ESKD
change in response to clinical intervention.
▸ Satisfaction with care will be evaluated using a
two-item scale that asks participants to rate their
degree of satisfaction with the care they receive for
their physical and mental health on a ﬁve-item Likert
response scale. This information will be assessed at
baseline and follow-up.
▸ Serious adverse events will be directly enquired about
using self-report at follow-up only, according to good
clinical practice guidelines. Participants will be asked
whether they have experienced any adverse events
since starting the study choosing from a list of ﬁve
options. If participants indicate they have experi-
enced adverse events then they will be asked for
details. In addition, participants will be asked if they
have experienced any adverse health effects since
starting the study and encouraged to elaborate where
needed.
▸ Treatments for depression and/or anxiety: Two brief
self-report questions at follow-up will ask participants
if they have received any pharmacological or psycho-
logical treatments for their depression and/or
anxiety in addition to the iDiD website since starting
the study.
Sociodemographic and clinical characteristics
Sociodemographic characteristics including: gender,
age, ethnicity, home environment (marital status,
housing situation, number of dependents) and level of
education will be collected at baseline only via self-
report. Clinical characteristics including: dialysis vintage
and treatment history for depression and anxiety will be
self-reported by patients at baseline.
Table 1 Schedule of assessments
Assessment
Time
Screening Baseline 3 months
PHQ-9 x x X
GAD-7 x x X
EQ-5D x X
Client service receipt
inventory
x X
Sociodemographics x
Clinical
characteristics
x
Biological clinical
outcomes
x x
Self-reported adverse
events
x
Self-reported
treatments for
depression and
anxiety during the
study
x
Brief illness
perception
questionnaire
x x
Satisfaction with care x x
Experience of using
the iDiD website
x
iDiD, Improving distress in dialysis.
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Number and type of comorbidities will be extracted
from notes at baseline only. The following clinical out-
comes and covariates will be extracted from notes at
baseline and follow-up: Kt/V (dialysis treatment
adequacy), haemoglobin, serum albumin, C reactive
protein, serum potassium levels, interdialytic weight gain
and serum phosphate levels.
QUALITATIVE INTERVIEWS
Qualitative interviews with a subgroup of participants
over the phone will be conducted postintervention
(3 months) by a researcher who has not been involved
in their treatment. These interviews will explore whether
the intervention met patient expectations, positive and
negative opinions about the website, whether patients
felt they gained any beneﬁt from using the website, its
personal relevance to them and its acceptability as a
treatment. A minimum of 10 participants will be purpos-
ively sampled across a range of sociodemographic and
clinical characteristics (eg, treatment group, age, gender,
ethnicity, dialysis vintage, degree of adherence to the
intervention, degree of improvements in outcomes from
the intervention). Interviews will continue until data sat-
uration occurs. The outcomes of these qualitative inter-
views will help to revise our theoretical understanding of
distress in dialysis and update the content of the inter-
vention accordingly, in line with current medical
research guidelines for process evaluations.40 Interviews
will be transcribed verbatim, and an inductive thematic
analysis will be performed.
SAMPLE SIZE
The aim of this study is to explore the feasibility of
implementing our trial procedures and to inform a
power calculation for a future RCT. We have calculated
the sample size required based on the margins of error
associated with recruitment. The approximate size of
the Guy’s and St Thomas’ dialysis population is 600
patients, in which we expect to be able to approach 400
of them. Assuming a conservative uptake rate of 50%,
200 patients will be screened, with approximately 40%
meeting the inclusion criteria (the estimated prevalence
of depression symptoms in HD patients4). If we assume
50% of those eligible will consent to be randomised, a
sample size of approximately 66 would allow us to esti-
mate the true population consent rate with a 5% margin
of error and a 95% conﬁdence level.
ANALYSIS PLAN
To examine the feasibility and acceptability of our
screening, recruitment, retention and randomisation
process (objectives 1–3), we will quantify the ﬂow of par-
ticipants through the study using frequencies and per-
centages in accordance with the consort ﬂow diagram35
shown in ﬁgure 2. We will also record and quantify
reasons for non-consent, exclusion and drop-out for
each stage of the study. We will examine degree of
adherence to the intervention and telephone support
calls (where applicable) using descriptive statistics
(objective 4).
We will also perform an exploratory intention-to-treat
mixed-model analysis blind to treatment group on the
following self-report outcomes at 3 months follow-up:
depression, anxiety and quality of life (objectives 5 and
6). Variability in these patient outcomes will help to
inform a future power calculation for a full-scale trial.
Service costs will be calculated by combining service
use data with appropriate unit costs.41 These will be
added to the costs of the intervention which will be
based on development costs and the time spent provid-
ing telephone support. Costs will be compared between
the two groups, and cost-effectiveness assessed by com-
bining the costs with the primary outcome measures and
quality-adjusted life years (QALYs) in the form of incre-
mental cost-effectiveness ratios (ICERs). Uncertainty
around the ICERs will be addressed using cost-
effectiveness planes and acceptability curves (objective
7). We will also perform an exploratory process analysis
using intention-to-treat mixed-models to establish
whether illness cognitions changed in response to the
online intervention and whether differences occurred
between the intervention and control group (objective
8). Qualitative interviews will be transcribed verbatim
and analysed using thematic analysis to allow the feasibil-
ity and acceptability of the online intervention and tele-
phone support calls to be explored (objective 9).
ETHICS
This study has ethical approval from the NHS research
ethics committee (14/LO/1934), and is sponsored by
King’s College London.
DATA COLLECTION AND MANAGEMENT
The IMPARTS screening interface, developed by
Teleologic Ltd, is web based and installed on the server
conﬁguration at Guy’s and St Thomas’ Hospitals NHS
Foundation Trust. The patient logs on to the system with
their unique Hospital Number. Their screening results
are outputted to the documents folder of the Electronic
Patient Record via the most secure WiFi network within
each NHS Trust.
All quantitative outcomes are measured via online
questionnaires that participants will access via iDiD
website. The information is stored on a secure server
associated with the Lifeguide programme at the
University of Southampton. The website prompts the
participant when data is missing. Study data can only be
downloaded from the server by members of the research
team who are granted password access. All data will be
conﬁdentially stored in accordance with the data protec-
tion act and King’s College London data management
procedures.
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FORMAL COMMITTEE
A trial management team will meet regularly to discuss
the overall running of the study including: rates of
recruitment, adherence to the protocol, safety and conﬁ-
dentiality of patients. All serious adverse events related
to the study will be reported to the study sponsor, ethics
committee and Guy’s and St Thomas’ research and
development department.
DISCUSSION
Psychological distress is common in people with ESKD.
However, studies examining the efﬁcacy of either
pharmacological or psychological interventions for the
management of distress in dialysis are limited. Likewise,
access to psychological treatment interventions tailored
to the speciﬁc psychosocial stresses associated with ESKD
is problematic. An online CBT treatment designed spe-
ciﬁcally to manage distress in dialysis offers a pragmatic
solution to under-resourced health services, which are
advised to offer integrated mental and physical health-
care treatments.
This is the ﬁrst study to examine whether it is feasible
to implement an RCT of online CBT with telephone
support versus online CBT without telephone support
within a stepped-care framework to secondary care
patients undergoing haemodialysis with comorbid dis-
tress. Indeed, it will identify unique challenges that
occur in the dialysis population in the recruitment and
retention of patients. Likewise, the study will be able to
simultaneously examine the acceptability of this treat-
ment to patients in terms of whether its content was
relevant and useful. In addition, the utility of the online
mode of delivery with or without telephone support will
be examined. We anticipate that the results of this trial
will substantially inform the design of a future
large-scale trial powered to detect the efﬁcacy of online
CBT treatments for the management of distress in
dialysis.
TRIAL STATUS
The study started recruitment in February 2015.
Recruitment is until February 2016 with the last patient’s
follow-up in May 2016. Outcomes will be disseminated at
national and international conferences, and in journal
articles.
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